Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 300

Conference Videos 8

Conference Information 1

Year

2024 18

2023 31

2022 28

2021 31

2020 15

2019 28

2018 15

2017 13

2016 17

2015 13

2014 13

2013 10

2012 20

2011 8

2010 11

2009 19

2008 5

2007 4

2000 3

1999 1

open ︾

Keywords

cancer 29

lung cancer 17

Cancer 9

immunotherapy 9

breast cancer 8

cervical cancer 8

targeted therapy 8

cancer therapy 7

therapy 6

Colorectal cancer 5

gene therapy 5

COVID-19 4

chemotherapy 4

epigenetics 4

meta-analysis 4

prostate cancer 4

cancer immunotherapy 3

colorectal cancer 3

drug resistance 3

open ︾

Search scope:

排序： Display mode:

Hydroxyl radical-involved cancer therapy via Fenton reactions

Frontiers of Chemical Science and Engineering 2022, Volume 16, Issue 3, Pages 345-363 doi: 10.1007/s11705-021-2077-3

Abstract: Therefore, supplying Fenton catalysts and elevating H₂O₂ levels into cancer cellsFurthermore, the challenges and future developments of hydroxyl radical-involved cancer therapy are discussed

Keywords： hydroxyl radical Fenton catalyst hydrogen peroxide cancer therapy

HTML PDF Collect

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Frontiers of Medicine 2021, Volume 15, Issue 2, Pages 221-231 doi: 10.1007/s11684-020-0812-7

Abstract: therapy in clinics.therapy, recent findings on the essential role of GSK3 in mediating cancer cell response to mTOR inhibitorsand mTORC1 inhibition-induced upregulation of PD-L1 in cancer cells may provide some explanations.These new findings may also offer us the opportunity to rationally utilize mTOR inhibitors in cancertherapy.

Keywords： mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1

HTML PDF Collect

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and inthyroid cancer, but also increasingly in various types of cancers at low rates.

Keywords： pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug

HTML PDF Collect

Bioorthogonal chemistry based on-demand drug delivery system in cancer therapy

Frontiers of Chemical Science and Engineering 2023, Volume 17, Issue 4, Pages 483-489 doi: 10.1007/s11705-022-2227-2

Abstract: commonly contains the “bond formation” and “bond cleavage” system has been widely used in targeted therapybioorthogonal reaction that tailoring the metabolic glycoengineering tactics to modified cells for cancerapplications, the complexities, potential pitfalls, and opportunities of bioorthogonal chemistry in future cancertherapy will be evaluated.

Keywords： bioorthogonal reaction cancer therapy metabolic glycoengineering bioorthogonal catalytic patch

HTML PDF Collect

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Frontiers of Medicine 2018, Volume 12, Issue 2, Pages 229-235 doi: 10.1007/s11684-017-0581-0

Abstract:

On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patientstreatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinomaTaking gastric cancer as an example, its molecular classification is built on genome abnormalities, butSubsequently, by using their findings, oncologists will carry out targeted therapy based on molecular

Keywords： molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H

HTML PDF Collect

Particle therapy for cancers: a new weapon in radiation therapy

Guo-Liang Jiang

Frontiers of Medicine 2012, Volume 6, Issue 2, Pages 165-172 doi: 10.1007/s11684-012-0196-4

Abstract: of physical dose distribution causes proton and carbon beams to optimally meet the requirement for cancerand intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in localCarbon therapy in Japan showed even more promising results than proton therapy.and overall survivals were as good as that treated by surgery in early stages of non-small cell lung cancerParticle therapy is gradually getting attention from the oncology community.

Keywords： radiation therapy particle therapy proton carbon cancer

HTML PDF Collect

How to judge the association of postmenopausal hormone therapy and the risk of breast cancer

Ling XU

Frontiers of Medicine 2010, Volume 4, Issue 3, Pages 290-293 doi: 10.1007/s11684-010-0093-7

Abstract: The relevance of postmenopausal hormone therapy (HT) for breast cancer risk has been long debated, althoughThese unanswered questions include: whether HT has a positive impact on breast cancer; whether risksof therapy with unopposed estrogen and combined estrogen-progestin are different; and whether differentHowever, a possible risk of breast cancer associated with long-term HT usage should not be ignored.With respect to prevention of breast cancer, regular evaluation of individual breast cancer susceptibility

Keywords： breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy

HTML PDF Collect

Unlocking the potential of bispecific ADCs for targeted cancer therapy

Frontiers of Medicine 2024, Volume 18, Issue 4, Pages 597-621 doi: 10.1007/s11684-024-1072-8

Abstract: drug delivery to tumor cells, minimizing harm to normal tissues and offering excellent prospects for cancerreview, we present available evidence and future prospects regarding the use of bispecific ADCs for cancerWe offer insights into the future development of bispecific ADCs to provide novel strategies for cancer

Keywords： antibody–drug conjugate bispecific antibody bispecific ADC cancer

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: Lung cancer is one of the most common human cancers and the number one cancer killer in the United StatesIn general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)The early diagnosis and therapy of lung cancer still presents a big challenge because validated screeningtherapy, and prognosis in NSCLC.Recent clinical data have revealed that targeted therapy might be the second-line therapy as an alternative

Keywords： lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5, Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapiesThis study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy

Keywords： anlotinib chemotherapy short-term relapsed small-cell lung cancer

HTML PDF Collect

Iron oxide nanoparticle-based theranostics for cancer imaging and therapy

Xiaoqing REN,Hongwei CHEN,Victor YANG,Duxin SUN

Frontiers of Chemical Science and Engineering 2014, Volume 8, Issue 3, Pages 253-264 doi: 10.1007/s11705-014-1425-y

Abstract: platform, which is equipped with both diagnostic and therapeutic functions, is a promising approach in cancerThis review is focused on the IONP-based nanotheranostics for cancer imaging and treatment.IONP-based diagnosis, magnetic resonance imaging (MRI), multimodal imaging, chemotherapy, hyperthermal therapy, photodynamic therapy, and gene delivery.

Keywords： theranostics iron oxide nanoparticles MRI drug delivery photothermal therapy photodynamic therapy

HTML PDF Collect

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Frontiers of Medicine 2021, Volume 15, Issue 1, Pages 1-10 doi: 10.1007/s11684-020-0741-5

Abstract: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous

Keywords： triple-negative breast cancer immunotherapy targeted therapy

HTML PDF Collect

Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic

Frontiers of Medicine 2023, Volume 17, Issue 6, Pages 1135-1169 doi: 10.1007/s11684-023-1050-6

Abstract: Pancreatic cancer, notorious for its late diagnosis and aggressive progression, poses a substantial challengeThis review endeavors to furnish a holistic insight into pancreatic cancer, encompassing its epidemiologyand explore recent research advancements in precursor lesions and molecular subtypes of pancreatic cancerAdditionally, we highlight the development and application of multi-omics approaches in pancreatic cancerresearch and discuss the latest combinations of pancreatic cancer biomarkers and their efficacy.

Keywords： pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy

HTML PDF Collect

Complex interplay between tumor microenvironment and cancer therapy

Minhong Shen, Yibin Kang

Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 426-439 doi: 10.1007/s11684-018-0663-7

Abstract: The TME is highly dynamic and its importance in different stages of cancer progression has been wellA growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses.TME is significantly remodeled upon cancer therapies, and such change either enhances the responses orGiven the importance of TME in tumor progression and therapy resistance, strategies that remodel TMEprovide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer

Keywords： tumor microenvironment therapy response treatment resistance

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: Immunotherapy plays a compelling role in cancer treatment and has already made remarkable progress.developed, such as small molecules, bispecific antibodies, chimeric antigen receptor T cell products, and cancerChimeric antigen receptor T cell products and cancer vaccines have also been investigated.

Keywords： cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer